17-(1,2-ethanediylacetal) (3α,5α,11β)-(3-methoxymethoxy)-11-hydroxyandrostan-17-one | 1355032-14-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-(1,2-ethanediylacetal) (3α,5α,11β)-(3-methoxymethoxy)-11-hydroxyandrostan-17-one
• 英文别名: (3α,5α,11β)-3-[[(methyloxy)methyl]oxy]-11-hydroxyandrostan-17-one, cyclic 17-(1,2-ethanediyl acetal)；(3R,5S,8S,9S,10S,11S,13S,14S)-3-(methoxymethoxy)-10,13-dimethylspiro[1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-17,2'-1,3-dioxolane]-11-ol
• CAS: 1355032-14-2
• 化学式: C₂₃H₃₈O₅
• 分子量: 394.552
• InChiKey: XGZHDONCNOXAJF-ILEJNFISSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  17-(1,2-ethanediylacetal) (3α,5α,11β)-(3-methoxymethoxy)-11-hydroxyandrostan-17-one 在 盐酸 、 potassium tert-butylate 、 potassium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 40.5h， 生成 (3α,5α,11β,17β)-spiro[11-(benzyloxy)androstane-17,2'-oxiran]-3-ol
  参考文献：
  名称：

  Neurosteroid Analogues. 17. Inverted Binding Orientations of Androsterone Enantiomers at the Steroid Potentiation Site on γ-Aminobutyric Acid Type A Receptors

  摘要：

  The enantiomer pair androsterone and ent-androsterone are positive allosteric modulators of gamma-aminobutyric acid (GABA) type A receptors. Each enantiomer was shown to bind at the same receptor site. Binding orientations of the enantiomers at this site were deduced using enantiomer pairs containing OBn substituents at either C-7 or C-11. 11 beta-OBn-substituted steroids and 7 alpha-OBn-substituted ent-steroids potently displace [S-35]-tert-butylbicyclophosphorothionate, augment GABA currents, and anesthetize tadpoles. In contrast, 7 beta-OBn-substituted steroids and 11 alpha-OBn-substituted ent-steroids have diminished actions. The results suggest that the binding orientations of the active analogues are inverted relative to each other with the 7 alpha- and 11 beta-substituents similarly located on the edges of the molecules not in contact with the receptor surface. Analogue potentiation of the GABA current was abrogated by an alpha(1) subunit Q241L mutation, indicating that the active analogues act at the same sites in alpha(1)beta(2)gamma(2L) receptors previously associated with positive neurosteroid modulation.

  DOI：

  10.1021/jm2014925
• 作为产物：
  描述：

  (3α,5α)-3-[[(methyloxy)methyl]oxy]androstane-11,17-dione, cyclic 17-(1,2-ethanediyl acetal) 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以80%的产率得到17-(1,2-ethanediylacetal) (3α,5α,11β)-(3-methoxymethoxy)-11-hydroxyandrostan-17-one
  参考文献：
  名称：

  Neurosteroid Analogues. 17. Inverted Binding Orientations of Androsterone Enantiomers at the Steroid Potentiation Site on γ-Aminobutyric Acid Type A Receptors

  摘要：

  The enantiomer pair androsterone and ent-androsterone are positive allosteric modulators of gamma-aminobutyric acid (GABA) type A receptors. Each enantiomer was shown to bind at the same receptor site. Binding orientations of the enantiomers at this site were deduced using enantiomer pairs containing OBn substituents at either C-7 or C-11. 11 beta-OBn-substituted steroids and 7 alpha-OBn-substituted ent-steroids potently displace [S-35]-tert-butylbicyclophosphorothionate, augment GABA currents, and anesthetize tadpoles. In contrast, 7 beta-OBn-substituted steroids and 11 alpha-OBn-substituted ent-steroids have diminished actions. The results suggest that the binding orientations of the active analogues are inverted relative to each other with the 7 alpha- and 11 beta-substituents similarly located on the edges of the molecules not in contact with the receptor surface. Analogue potentiation of the GABA current was abrogated by an alpha(1) subunit Q241L mutation, indicating that the active analogues act at the same sites in alpha(1)beta(2)gamma(2L) receptors previously associated with positive neurosteroid modulation.

  DOI：

  10.1021/jm2014925

文献信息

• NEUROACTIVE 17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
  申请人：Covey Douglas

  公开号：US20140309443A1

  公开（公告）日：2014-10-16

  The present disclosure is generally directed to neuroactive 17(20)-Z-vinylcyano-substituted compound of Formula (I) and (II), as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

  本公开涉及一般指向化合物的神经活性17(20)-Z-乙烯基氰基取代物，其化学式为(I)和(II)，并且其药学上可接受的盐，例如用作麻醉剂，和/或用于治疗与GABA功能和活性相关的疾病。本公开还涉及包含这种化合物的药物组合物。